PO Box 429
Falls Village, CT 06031
Hollenbeck’s HOL-101 has an orphan drug designation to treat Growth Hormone Deficiency (GHD) in adults and children. Hollenbeck has applied for Orphan Designation for its diagnostic which will diagnose GHD in adults and children. As time and funding permit, Hollenbeck plans to investigate other applications of HOL-101.
Hollenbeck expects to begin trials of the diagnostic and its treatment for GHD in adults and children in late 2021.
Hollenbeck is a private company.